Clin2
NCT06372587Possibly a fitRecruiting

Next-generation Alzheimer's treatment study

Alzheimer Disease

Part of Brain & nervous system, Mental health clinical trials.

This study tests a new treatment for people with probable Alzheimer's disease. It aims to see if the treatment is safe and effective for patients between 18 and 80 years old.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
14 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You have been diagnosed with probable Alzheimer's disease
  • You are between 18 and 80 years old
  • You are able to give informed consent
  • You do NOT have other neurological disorders (like Parkinson's or stroke)
  • You do NOT have bleeding problems or take blood thinners
  • You do NOT have serious skin or connective tissue diseases

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06677632Not yet recruiting
Targeting zDHHC enzymes to treat Alzheimer's disease

This trial tests a new treatment that targets certain enzymes (zDHHC) to help fight Alzheimer's disease. It is for adults with Alzheimer's who do not have other major health conditions.

Roma
NCT06957418Recruiting· Phase 2
Alzheimer's tau drug study for early stage patients

This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.

San Francisco, California
NCT07221344Recruiting· Phase 1/Phase 2
Study of an experimental drug for early Alzheimer's disease

This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.

East York, Ontario
NCT04902703Recruiting· Phase 2
GM-CSF drug trial for mild to moderate Alzheimer’s disease

This Phase 2 study tests whether sargramostim (a GM-CSF related medicine) is safe and can slow or improve Alzheimer’s symptoms. You might be a good fit if you have mild or moderate Alzheimer’s, positive amyloid testing, and can complete frequent visits with a close caregiver who knows you well.

Aurora, Colorado
NCT07058688Recruiting· Phase 2
Testing a new drug for Alzheimer's (NTRX-07)

This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.

Brno
NCT06535308Recruiting· Phase 1
Testing a new Alzheimer's drug for moderate disease

This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.

Seoul, Jongno-gu

Hear when a new Alzheimer Disease trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.